

112

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
15878

In Re Application Of: Todd Charlton Sacktor, et al.

APR 16 2007
PATENT & TRADEMARK OFFICE

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/533,595	April 27, 2006	Chang Yu Wang	23389	1649	6263

Title:

**ATYPICAL PROTEIN KINASE C ISOFORMS IN DISORDERS OF THE NERVOUS SYSTEM
AND CANCER**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT(Under 37 CFR 1.97(b) or 1.97(c)) **PE**

Docket No.

15878

In Re Application of: **Todd Charlton Sacktor, et al.**

APR 16 2007

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/533,595	April 27, 2006	Chang Yu Wang	23389	1649	6263

Title:

ATYPICAL PROTEIN KINASE C ISOFORMS IN DISORDERS OF THE NERVOUS SYSTEM AND CANCER**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))


- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**Certificate of Transmission by Facsimile***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa	
(Date)	
Signature	
Typed or Printed Name of Person Signing Certificate	

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on	
April 10, 2007	
(Date)	
Signature of Person Mailing Correspondence	
Peter I. Bernstein	
Typed or Printed Name of Person Mailing Certificate	

***This certificate may only be used if paying by deposit account.**

Signature

Dated: April 10, 2007

Peter I. Bernstein
Registration No. 43,497
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Todd Charlton Sacktor, et al. **Examiner:** Chang Yu Wang
Serial No.: 10/533,595 **Art Unit:** 1649
Filed: April 27, 2006 **Docket:** 15878
For: ATYPICAL PROTEIN KINASE **Dated:** April 10, 2007
C ISOFORMS IN DISORDERS OF THE
NERVOUS SYSTEM AND CANCER

Confirmation No.: 6263

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

STATEMENT PURSUANT TO 37 C.F.R. §1.704(d)


Sir:

I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 10, 2007



Peter I. Bernstein

Therefore, this Information Disclosure Statement cannot be considered a failure to engage in reasonable efforts to conclude prosecution of the application under paragraphs (c)(6), (c) (8), (c) (9), or (c) (10) of 37 C.F.R. § 1.704.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'P. Bernstein', with a long horizontal flourish extending to the right.

Peter I. Bernstein
Registration No. 43,497

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB:dg



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Todd Charlton Sacktor, et al. **Examiner:** Chang Yu Wang
Serial No.: 10/533,595 **Art Unit:** 1649
Filed: April 27, 2006 **Docket:** 15878
For: ATYPICAL PROTEIN KINASE **Dated:** April 10, 2007
C ISOFORMS IN DISORDERS OF THE
NERVOUS SYSTEM AND CANCER

Confirmation No.: 6263

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. PCT International Publication No. WO 01/80875 A1, published November 1, 2001;
2. Moore P. et al., "Protein Kinase C- ζ Activity But Not Level is Decreased in Alzheimer's Disease Microvessels", *Neuroscience Letters* 254(1):29-32 (1998), XP-002406082;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 10, 2007


Peter I. Bernstein

3. Xie J. et al., "Protein Kinase C Iota Protects Neural Cells Against Apoptosis Induced by Amyloid β -Peptide", *Molecular Brain Research* 82(1-2):107-113 (2000), XP-002406083;
4. Roßner S. et al., "Increased Neuronal and Glial Expression of Protein Kinase C Isoforms in Neocortex of Transgenic Tg2576 Mice With Amyloid Pathology", *European Journal of Neuroscience* 13(2):269-278 (2001), XP-002327322;
5. PCT International Publication No. WO 02/087417 A2, published November 7, 2002; and
6. Barad M. et al., "Mice Overexpressing a Constitutively Active PKM ζ Derived Transgene in Brain Under CAMKII Promoter Control, Show Defects in Memory and Increased Incidence of Neurofibromas", *Abstracts of the Society for Neuroscience, Society for Neuroscience* 24(1-2):328 (1998), XP-002967921 (Abstract).

The references were cited in a Supplementary Partial Search Report dated March 15, 2007 received from the European Patent Office. Applicants are submitting a copy of the above-cited references, together with a copy of the Supplementary Partial Search Report. Please note that the other reference cited in the Supplementary Partial Search Report, namely, Shao C.Y. et al., "Atypical Protein Kinase C (PKC) Colocalizes with Tau-and α -Synuclein-Related Inclusions in Neurodegenerative Disorders", *Society for Neuroscience Abstracts* 02-07 (2002), Abstract 592.9 was previously submitted in applicant's Information Disclosure Statement dated June 16, 2005. The relevance of the above-identified references has been described in the Supplementary Partial Search Report.

Further, the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Inasmuch as this Information Disclosure Statement is also being submitted in accordance with the schedule set out in 37 C.F.R. § 1.704(d), a statement is attached.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Peter I. Bernstein', written over a circular stamp or mark.

Peter I. Bernstein
Registration No. 43,497

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB:dg

Form PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**LIST OF PRIOR ART
CITED BY APPLICANT***(Use several sheets if necessary)*

Atty. Docket No. (Optional)

15878

Application Number

10/533,595

Applicant(s)

Todd Charlton Sacktor, et al.

Filing Date

April 27, 2006

Group Art Unit

1649

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/80875 A1	11/1/01	PCT			✓	
	WO 02/087417 A2	11/7/02	PCT			✓	

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Moore P. et al., "Protein Kinase C- ζ Activity But Not Level is Decreased in Alzheimer's Disease Microvessels", <i>Neuroscience Letters</i> 254(1):29-32 (1998), XP-002406082
	Xie J. et al., "Protein Kinase C Iota Protects Neural Cells Against Apoptosis Induced by Amyloid β -Peptide", <i>Molecular Brain Research</i> 82(1-2):107-113 (2000), XP-002406083
	Roßner S. et al., "Increased Neuronal and Glial Expression of Protein Kinase C Isoforms in Neocortex of Transgenic Tg2576 Mice With Amyloid Pathology", <i>European Journal of Neuroscience</i> 13(2):269-278 (2001), XP-002327322
	Barad M. et al., "Mice Overexpressing a Constitutively Active PKM ζ Derived Transgene in Brain Under CAMKII Promoter Control, Show Defects in Memory and Increased Incidence of Neurofibromas", <i>Abstracts of the Society for Neuroscience, Society for Neuroscience</i> 24(1-2):328 (1998), XP-002967921 (Abstract)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.